Long Branch, NJ, United States
Long Branch, NJ, United States

Time filter

Source Type

Brouwer M.C.,University of Amsterdam | Thwaites G.E.,King's College London | Thwaites G.E.,Guys and St Thomas NHS Foundation Trust | Tunkel A.R.,Monmouth Medical Center | Van De Beek D.,University of Amsterdam
The Lancet | Year: 2012

Rapid diagnosis and treatment of acute community-acquired bacterial meningitis reduces mortality and neurological sequelae, but can be delayed by atypical presentation, assessment of lumbar puncture safety, and poor sensitivity of standard diagnostic microbiology. Thus, diagnostic dilemmas are common in patients with suspected acute community-acquired bacterial meningitis. History and physical examination alone are sometimes not suffi cient to confi rm or exclude the diagnosis. Lumbar puncture is an essential investigation, but can be delayed by brain imaging. Results of cerebrospinal fl uid (CSF) examination should be interpreted carefully, because CSF abnormalities vary according to the cause, patient's age and immune status, and previous treatment. Diagnostic prediction models that use a combination of clinical fi ndings, with or without test results, can help to distinguish acute bacterial meningitis from other causes, but these models are not infallible. We review the dilemmas in the diagnosis of acute communityacquired bacterial meningitis, and focus on the roles of clinical assessment and CSF examination.

Van De Beek D.,University of Amsterdam | Brouwer M.C.,University of Amsterdam | Thwaites G.E.,King's College London | Thwaites G.E.,Guys and St Thomas NHS Foundation Trust | Tunkel A.R.,Monmouth Medical Center
The Lancet | Year: 2012

Bacterial meningitis kills or maims about a fi fth of people with the disease. Early antibiotic treatment improves outcomes, but the eff ectiveness of widely available antibiotics is threatened by global emergence of multidrug-resistant bacteria. New antibiotics, such as fl uoroquinolones, could have a role in these circumstances, but clinical data to support this notion are scarce. Additionally, whether or not adjunctive anti-infl ammatory therapies (eg, dexamethasone) improve outcomes in patients with bacterial meningitis remains controversial; in resource-poor regions, where the disease burden is highest, dexamethasone is ineff ective. Other adjunctive therapeutic strategies, such as glycerol, paracetamol, and induction of hypothermia, are being tested further. Therefore, bacterial meningitis is a substantial and evolving therapeutic challenge. We review this challenge, with a focus on strategies to optimise antibiotic effi cacy in view of increasingly drug-resistant bacteria, and discuss the role of current and future adjunctive therapies.

News Article | November 1, 2016
Site: www.24-7pressrelease.com

SPRING LAKE, NJ, November 01, 2016-- John T. Harrigan, MD, has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.With more than 60 years of experience in the medical field, Dr. Harrigan is widely regarded as a leader in women's health care. He is responsible for establishing three perinatal centers in New Jersey, in addition to previously serving as the section chairman of the American College of Obstetricians and Gynecologists. As the former president of the Perinatal Association, Dr. Harrigan is actively involved with numerous medical associations, including the Medical Society of New Jersey, the New Jersey Perinatal Association, the American Medical Association, the American Institute of Ultrasound in Medicine and the American Fertility Society.Dr. Harrigan began his career upon graduating from George Washington University with an MD in 1953. He served as an attending in obstetrics-gynecology at Martland Hospital Unit between 1970 and 1974 before joining Monmouth Medical Center as a director of the department of obstetrics-gynecology and associate professor. A diplomate with the American Board of Obstetrics and Gynecology, Dr. Harrigan entered private practice in 1960 with a sub-specialty in maternal-fetal medicine. He continues to serve the community as a renowned physician, professor and author. Most recently, he has taken a keen interest in the relation between religious spirituality and health.Since 1986, Dr. Harrigan has served the University of Medicine and Dentistry Rutgers Medical School as a professor of obstetrics-gynecology and as a director of the division of maternal-fetal medicine. He is a consultant in maternal-fetal medicine to physicians throughout eastern New Jersey, and has contributed articles to medical journals pertaining to his areas of expertise. In recognition of his contributions to medicine, Dr. Harrigan has been featured in a wide variety of honors publications, including Who's Who in America, Who's Who in Medicine and Healthcare, Who's Who in the East and Who's Who in the World. In addition, he was included in the 3rd edition of Who's Who Among Human Services Professionals.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis now publishes many Who's Who titles, including Who's Who in America , Who's Who in the World , Who's Who in American Law , Who's Who in Medicine and Healthcare , Who's Who in Science and Engineering , and Who's Who in Asia . Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com

News Article | November 16, 2016
Site: www.prweb.com

On Monday, November 7, 2016, board-certified orthopedic spine surgeon Dr. Nasser Ani performed a minimally invasive anterior cervical discectomy and fusion (ACDF) surgery on a 56-year-old female patient who was experiencing severe arm pain and numbness. The surgery took place at the Metropolitan Surgical Institute, an outpatient surgical center in South Amboy, New Jersey. The patient was suffering from cervical radiculopathy, with symptoms of radiating arm pain, as a result of a severe disc herniation causing compression of the spinal nerve roots at levels C5-6 and C6-7. After failed conservative treatment including physical therapy and spine epidural injections, the patient elected to have a two-level anterior cervical discectomy and fusion. Dr. Ani utilized a minimally invasive surgery to address the patient’s cervical radiculopathy and disc herniation. He chose an anterior surgical approach to gain exposure to the cervical spine through a small transverse incision in the neck. Dr. Ani was able to remove the herniated discs, and free the compressed and pinched nerves. After the discectomy, Dr. Ani inserted SpineFrontier’s biocompatible LES ARENA-C (HA) cervical cages to restore natural disc height between the vertebral bodies using the Less Exposure Surgery (LES) technique and placed a low-profile, two-level LES INVUE MAX cervical plate on the operative levels to provide stability until fusion takes place. Dr. Ani commented on the case: “The LES INVUE plate, when paired with the LES ARENA-C (HA) interbody, was one of the safest, most efficient ways to stabilize this patient’s spine. The instruments and procedural steps are easy. The hydroxyapatite (HA) infused LES ARENA-C spacer, together with a cancellous bone sponge and the patient’s own stem cells will result in an excellent fusion.” Dr. Ani stated that “minimally invasive surgery enables patients to return home just hours after surgery with little to no pain. This patient will be able to return to work in two to three weeks.” Dr. Nasser Ani is a board-certified orthopedic and spine surgeon at Ani Medical Group, Orthopedic and Spine Institute of New Jersey and deals with all aspects of spinal disorders, deformities and scoliosis. Initially, patients are treated in a conservative fashion in an effort to provide pain relief and help them return to functional status. However, in some cases, when conservative treatments fails, surgical options are discussed as a means to return patients back to their normal daily living activities. Dr. Ani is affiliated with multiple hospitals in the area, including Bayshore Community Hospital, Riverview Medical Center, Raritan Bay Medical Center, and Monmouth Medical Center. He is also the Chief of Orthopedics at Bayshore Community Hospital. He received his medical degree from the American University of Beirut, Lebanon. He completed an orthopedic surgery and spine fellowship at McGill University in Montreal, Canada. Dr. Ani has been in practice for over 25 years, double boarded in the fields of orthopedics and spinal surgery, and holds several professional affiliations including the North American Spine Society, Fellow of the American Academy of Orthopedics Surgeons, Fellow of the American College of Surgeons, Fellow of the Royal College of Surgeons, American Society for Laser Medicine and Surgery, and the American Medical Association, just to name a few. About SpineFrontier® Inc. SpineFrontier Inc. (http://www.spinefrontier.com) is a growing medical technology company that designs, develops and markets both implants and instruments for spine surgery based on the Less Exposure Surgery (LES®) Philosophy. These technologies are designed to allow for outpatient surgery due to minimal disruption of normal tissues. SpineFrontier is headquartered in Malden, MA. It is a KICVentures portfolio company and the leader in LES® technologies and instruments. About Less Exposure Surgery Less Exposure Surgery (LES®) is based on a new philosophy of performing surgery. LES® is less invasive than MIS. By developing improved technologies and techniques tailored for pinpointing a problem and fixing it without collateral damage, LES® minimizes tissue disruption.

Kaneko Y.,Ono Pharmaceutical Co. | Szallasi A.,Monmouth Medical Center
British Journal of Pharmacology | Year: 2014

Transient receptor potential (TRP) channels are important mediators of sensory signals with marked effects on cellular functions and signalling pathways. Indeed, mutations in genes encoding TRP channels are the cause of several inherited diseases in humans (the so-called 'TRP channelopathies') that affect the cardiovascular, renal, skeletal and nervous systems. TRP channels are also promising targets for drug discovery. The initial focus of research was on TRP channels that are expressed on nociceptive neurons. Indeed, a number of potent, small-molecule TRPV1, TRPV3 and TRPA1 antagonists have already entered clinical trials as novel analgesic agents. There has been a recent upsurge in the amount of work that expands TRP channel drug discovery efforts into new disease areas such as asthma, cancer, anxiety, cardiac hypertrophy, as well as obesity and metabolic disorders. A better understanding of TRP channel functions in health and disease should lead to the discovery of first-in-class drugs for these intractable diseases. With this review, we hope to capture the current state of this rapidly expanding and changing field. Linked Articles This article is part of a themed section on the pharmacology of TRP channels. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171. issue-10 © 2013 The British Pharmacological Society.

News Article | November 18, 2016
Site: www.prweb.com

CURE® Media Group, publishers of CURE® magazine, awards Gary Mervis, Dellann Elliott Mydland and Sumul N. Raval, MD, DABPH as the 2016 winners of its second annual Glioblastoma Multiforme (GBM) Heroes® Award, announced president of CURE® Media Group, Michael J. Hennessy, Jr. The winners will be honored at a celebration gala at the Fairmont Scottsdale Princess resort in Scottsdale, AZ, on Friday, November 18th. Additionally, this will take place during the 21st Annual Scientific Meeting of the Society for Neuro-Oncology. In making the announcement, Michael J. Hennessy, Jr., said “Our GBM Heroes® have made a significant difference in the lives of patients diagnosed with GBM. We are proud to celebrate their contributions and efforts in the areas of advocacy, treatment advances for this disease, and in improving the quality of life of patients and their families.” Guest speaker for the evening will be actress, author and 16-year uterine cancer survivor Fran Drescher, who has a reputation for passion and commitment. Her portrayal of Miss Fine on NBC's hit series The Nanny earned her two Emmy and two Golden Globe award nominations. She is an accomplished author and received the NCCS writer's award for Cancer Schmancer, a New York Times bestseller. Ms. Drescher is the founder, president and visionary of the nonprofit Cancer Schmancer Movement, which focuses on early detection, prevention and advocacy to fight the disease. The honorees of the 2016 award were nominated by patients, health care professionals and advocates for their contributions to the field of GBM and for making a difference in the lives of people with the disease. GBM is the most aggressive and most common form of primary brain tumor in the United States, affecting approximately 10,000 people every year. The median overall survival time from initial diagnosis is 15 months. Gary Mervis In 1979, Mervis learned that his youngest daughter suffered from a malignant brain tumor. In response to her diagnosis, he founded Camp Good Days and Special Times, Inc., a not-for-profit organization that focuses on improving the quality of life for children and families whose lives have been touched by cancer and other life challenges. Over the years, Camp Good Days and Special Times has served more than 46,700 campers from 22 states and 34 countries. Dellann Elliott Mydland In 2002, Mydland and her late husband, Christopher Steward Elliott, founded the EndBrainCancer Initiative (EBCI), which has as its goal to provide immediate access to top brain cancer specialists, including neurosurgeons and advanced treatment/clinical trials through a one-on-one personalized “direct connect” approach. Mydland is responsible for the organization's vision and is the driving force behind EBCI's goals to create effective change in health policy and standards of care. Sumul N. Raval, MD, DABPN Raval, a board-certified neurologist and authority on brain tumors, is one of the few neuro-oncologists in private practice who brings world-class care to families throughout New York and New Jersey. He is the founder and director of the David S. Zocchi Brain Tumor Center at Monmouth Medical Center in New Jersey, the state's first facility to specialize in brain tumors. Dr. Raval has received numerous awards, including “The Jersey Choice Top Doctors in New Jersey,” by New Jersey Monthly for the past four years. The GBM Heroes® Recognition program is sponsored by Novocure, a global oncology company. About CURE® magazine CURE® magazine is CURE® Media Group’s flagship product and an indispensable guide to every stage of the cancer continuum. With nearly 1 million readers who include cancer patients, cancer centers and advocacy groups, CURE® is the largest consumer publication in the U.S. that focuses solely on cancer. CURE® Media Group was acquired in 2014 by Michael J. Hennessy Associates, Inc. (MJH), and joined CURE® with MJH’s acclaimed OncLive® (http://www.onclive.com) platform of resources for the practicing oncologist. About Novocure Novocure is a global oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields. Headquartered in Jersey Isle, Novocure’s U.S. operations are based in Portsmouth, NH, and New York, NY. The company also has offices in Switzerland, Germany, and Japan, and a research center in Haifa, Israel. About Cancer Schmancer Cancer Schmancer, a tax-exempt organization based in Malibu, CA, was founded by Fran Drescher. The organization’s mission is to save lives by shifting the nation’s focus from just searching for a cure for cancer to prevention and early detection. The Cancer Schmancer Movement is a three-pronged movement dedicated to early cancer detection, prevention and policy change.

Mathis A.S.,Monmouth Medical Center
The American journal of managed care | Year: 2012

Infection with hepatitis C virus (HCV) is associated with significant morbidity, mortality, and economic burden. However, HCV infection is challenging to treat, because it is underdiagnosed and undertreated. When patients receive standard therapies, sustained virological response is usually achieved in less than 50% of cases. Newer therapies improve the virological and liverrelated outcomes associated with HCV, but at an increased cost of treatment. Because the economic burden of HCV extends beyond treatment costs, clinicians, patients, and managed care professionals must understand the cost-effectiveness of HCV treatment. Improvements in adherence and the delivery of effective care can promote costeffective management due to reductions in long-term disease-related complications, such as hospitalization, liver transplantation, and death.

Szallasi A.,Monmouth Medical Center | Sheta M.,Monmouth Medical Center
Expert Opinion on Investigational Drugs | Year: 2012

Introduction: With 336 reviews, the capsaicin receptor TRPV1 arguably represent today's most extensively reviewed analgesic target. TRPV1 is strategically located at the peripheral terminals of primary sensory neurons where pain is generated. TRPV1 as a target for analgesic drugs has been validated in preclinical studies. Areas covered: The therapeutic potential of targeting TRPV1 by agonists and antagonists for pain relief is discussed based on our experience and a critical review of the literature. Strategies to overcome adverse effects are explored. Expert opinion: Since its discovery in 1997, TRPV1 has run the gamut from excitement to disappointment to cautious optimism. Topical capsaicin has been disappointing for pain relief. By contrast, intrathecal resiniferatoxin is currently undergoing clinical trials in patients with intractable cancer pain. Some of the small-molecule TRPV1 antagonists have successfully passed Phase I safety and tolerability studies in healthy volunteers into Phase II studies to access efficacy in patients. Others showed worrisome unforeseen adverse effects, most important, hyperthermia and impaired noxious heat sensation. We conclude that TRPV1 blockade and desensitization are two promising, complimentary approaches for pain relief. Despite the roadblocks, TRPV1 remains a powerful tool in pain research and a promising therapeutic target. © 2012 Informa UK, Ltd.

Van De Beek D.,University of Amsterdam | Drake J.M.,University of Toronto | Tunkel A.R.,Monmouth Medical Center
New England Journal of Medicine | Year: 2010

Nosocomial bacterial meningitis is most often related to either complicated head trauma or invasive procedures, such as craniotomy, placement of ventricular catheters, intrathecal infusion of medications, or spinal anesthesia. In addition, metastatic infection from hospital-acquired bacteremia occasionally leads to meningitis. The conditions are associated with different pathogenetic mechanisms and a different spectrum of microorganisms, and therefore the choice of empirical antimicrobial therapy will vary according to the condition. Copyright © 2010 Massachusetts Medical Society.

Mathis A.S.,Monmouth Medical Center
American Journal of Managed Care | Year: 2013

Multiple sclerosis (MS) is associated with significant direct and indirect costs. Pharmacoeconomic studies of MS therapies have generally shown results which were not considered to be cost-effective when incremental cost-effectiveness ratios were analyzed for quality-adjusted life-years. When prevented relapses were considered as an end point, the cost-effectiveness results were generally more favorable, although the studies analyzed were limited by assumptions, projected outcomes, and lack of data on adverse events. Managed care professionals and clinicians can ensure maximized effectiveness of therapy by supporting adherence and by providing disease therapy management programs. Specialty pharmacies are an effective way to control costs and optimize the involvement of patients in their care.

Loading Monmouth Medical Center collaborators
Loading Monmouth Medical Center collaborators